News

PS-Fertility, maker of a male fertility test, to establish HQ outside Charlottesville

Life sciences startup PS-Fertility Inc. will invest $1.4 million to build out a headquarters and laboratory in Albemarle County, the office of Virginia Gov. Glenn Youngkin announced Wednesday.

PS-Fertility is aiming to commercialize a male fertility diagnostic that was originally developed at the University of Virginia. The company will lease 4,000 square feet at 3030 Vision Lane, just south of Charlottesville’s city limits, for its headquarters and lab as well as a test kit assembly operation, according to the announcement. PS-Fertility said it plans to create 31 new jobs with the project.

The company’s diagnostic tests for the presence of a biomarker on sperm cells necessary for fertilization, which can offer information on male fertility. PS-Fertility plans to use an at-home collection model, where samples are mailed to the new lab from across the country.

CEO Kevin Combs said in a statement his company planned to launch “in the very near future.”

The Virginia Economic Development Partnership said it worked with Albemarle County to secure the project for the state. Its Virginia Jobs Investment Program will support PS-Fertility’s hiring efforts by providing consultative services and funding to support recruitment and training.

“Virginia is the birthplace of innovations, and PS-Fertility’s groundbreaking discovery demonstrates the importance of our entrepreneurial ecosystems that lead to new technologies and products, ultimately resulting in new jobs,” Caren Merrick, Virginia’s secretary of commerce and trade, said in a statement.

Read more here.

Recent News

06/25/2025

Liquet Medical Closes Oversubscribed Seed Round to Launch Pilot Study Evaluating Real-Time Hemodynamic Monitoring

Liquet Medical, a clinical-stage medical device company developing the Versus™ Catheter — a first-of-its-kind dual-tipped catheter system cleared by the FDA for controlled and selective infusion of fluids into the pulmonary vasculature and hemodynamic monitoring — announced the successful and oversubscribed close of its Seed funding round, which officially closed in May 2025. The capital

06/25/2025

Adial Pharmaceuticals Secures U.S.-Based Manufacturing Through Agreements with Cambrex and Thermo Fisher Scientific for Drug Substance and Drug Product Supply

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced the recent execution of agreements for the production of AD04 (0.33 mg ondansetron tablets), supporting both the completion of upcoming clinical trials and the planned New Drug Application (NDA) submission to the U.S.

06/24/2025

AgroSpheres and Wilbur-Ellis Launch FUN-THYME™, a Powerful Broad-Spectrum Biofungicide Built on Novel AgriCell® Technology

AgroSpheres, a biotechnology company transforming crop protection with biobased innovations, today announced the commercial launch of FUN-THYME™, a groundbreaking, broad-spectrum biofungicide derived from thyme oil and delivered through the company’s proprietary AgriCell encapsulation platform. Through an exclusive distribution agreement, Wilbur-Ellis will introduce FUN-THYME™ to growers across the United States, helping them protect high-value crops including